Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Overview
- Why focus on M&E for NTDs?
- Substantial gaps exist in M&E for each NTD
- From M&E to MERLA
- MERLA
- MERLA cycle
- Stakeholders engaged in MERLA for NTDs
- Key indicators for NTDs
- Selecting indicators (1)
- Selecting indicators (2)
- Best practices for NTD indicator selection
- Key indicators for NTDS: PC for LF
- Indicator resources for NTDs
- NTD data collection
- Data collection sources and processes
- Best practices for NTD data collection (1)
- Best practices for NTD data collection (2)
- Resources for NTD data collection
- Data storage for NTD data
- Possible data storage systems and processes
- Best practices for NTD data storage
- Resources for NTD data storage
- Data validation for NTD data
- Options for NTD data validation
- Best practices for NTD data validation
- Resources for NTD data validation
- NTD data analysis and synthesis
- Options for NTD data analysis and synthesis
- Best practices for NTD data analysis and synthesis
- Resources for NTD data analysis and synthesis
- NTD data dissemination and use
- Considerations for NTD data dissemination and use
- NTD data dissemination and use
- Applying anticolonial practices
- Best practices for NTD data dissemination and use
- Resources for NTD data dissemination and use
- Take-home messages (1)
- Take-home messages (2)
- Acknowledgements
- Disclaimer
Topics Covered
- Neglected Tropical Disease (NTD)
- Monitoring, Evaluation (M&E)
- Monitoring, Evaluation, Research, Learning and Adapting (MERLA)
- Key indicators for NTDs
- NTD indicator selection
- NTD data collection, storage, validation, analysis, dissemination and use
Links
Series:
Categories:
Therapeutic Areas:
External Links
- Coalition for Operational Research on Neglected Tropical Diseases (COR-NTD)
- Slide 4, 14, 16, 17, 21, 22, 26, 30, 36 & 39 | WHO: Ending the neglect to attain the sustainable development goals: a framework for monitoring and evaluating progress of the road map for neglected tropical diseases 2021−2030
- Slide 14 | ESPEN Country NTD Master Plans
- Slide 14 | WHO: 2018 Global reference list of 100 core health indicators
- Slide 19 & 37 | WHO: Control of Neglected Tropical Diseases
- Slide 19 | Tropical data
- Slide 19 | Daily Data Reporting and Use During Mass Drug Administration for Neglected Tropical Disease Control
- Slide 23 | WHO: Analysis and use of health facility data
- Slide 23 | WHO: Guidance for community health workers strategic information and service monitoring
- Slide 27 | WHO: Preventive chemotherapy
- Slide 27 | COR-NTD: Coverage Evaluation Surveys
- Slide 27 | Data Quality Assessment during Supervision (DQA-S) for PC of NTDs
- Slide 27 | Job aid: When to use which key PC NTD M&E tool
- Slide 31 | PAHO tools for monitoring the coverage of integrated public health interventions
- Slide 31 | Coverage Survey Analysis Tool
- Slide 31 & 37 | ESPEN: Expanded Special Project for the Elimination of Neglected Tropical Diseases Portal
- Slide 33 | The digital difference in measuring production performance
- Slide 37 | WHO: NTD Progress Dashboard
- Slide 37 | USAID Learning Lab
- Slide 37 | ENVISION Data for Action Guide
- Slide 37 | NTD Tool box: How to Respond When NTD Survey Results Show that More Mass Drug Administration (MDA) is Needed
- Slide 37 | NTD Tool box: Reflection Session Guide for Ethiopia’s National NTD Program
- Slide 37 | WHO: Microplanning manual to guide implementation of preventive chemotherapy to control and eliminate neglected tropical diseases
Talk Citation
Zoerhoff, K. (2024, January 31). Monitoring, evaluation, research, learning and adapting for NTD programs [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/MKXR8307.Export Citation (RIS)
Publication History
Financial Disclosures
- Ms. Katie Zoerhoff has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
HSTalks is pleased to grant unrestricted complimentary access to all lectures in the series Neglected Tropical Diseases. Persons not at a subscribing institution should sign up for a personal account.
Other Talks in the Series: Neglected Tropical Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is
Katie Zoerhoff and I
serve as the Director of
a Neglected Tropical
Disease Data Center
at the Task Force
for Global Health.
Today, I'm going
to share with you
about monitoring,
evaluation, research,
learning, and adapting, or
MERLA for Neglected
Tropical Disease programs.
0:21
During this presentation,
I'll talk about why
we should focus on
monitoring and evaluation,
or M&E, for NTDs
and the shift from M&E to MERLA.
I'll then discuss key indicators
for NTDs and walk through
key activities along
the data pipeline
such as data collection,
data storage, validation,
analysis and synthesis,
and data dissemination and use.
I'll then wrap up with key
take-home messages
and acknowledgments.
I want to recognize that many of
the concepts included
in this presentation
are drawn from
WHO's M&A framework
that accompanies
the 2030 roadmap,
ending the neglect to
attain sustainable
development goals-
a framework for monitoring and
evaluating the progress
of the roadmap
through neglected tropical
diseases, 2021-2030.
1:09
First, why should we
focus on monitoring and
evaluation for NTDs?
1:16
There are substantial
gaps in monitoring
evaluation for each
NTD as identified
through various technical
consultations and reported
in WHO's 2030 roadmap for NTDs.
You can see here on this
slide that no disease was
classified as green for not
having any hindrances
toward the targets.
11 of the 24 required
critical action to be
able to adequately
implement M&E as of 2020.
These gaps make it
really difficult for
communities, national
NTD programs,
and the global community
to measure progress
toward disease,
eradication, elimination,
and control,
and to take steps to
accelerate that progress.
Hide